These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 8453688

  • 1. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.
    Marsh JH, Kreis W, Barile B, Akerman S, Schulman P, Allen SL, DeMarco LC, Schuster MW, Budman DR.
    Cancer Chemother Pharmacol; 1993; 31(6):481-4. PubMed ID: 8453688
    [Abstract] [Full Text] [Related]

  • 2. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
    Kreis W, Budman DR, Chan K, Allen SL, Schulman P, Lichtman S, Weiselberg L, Schuster M, Freeman J, Akerman S.
    Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
    [Abstract] [Full Text] [Related]

  • 3. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
    Amadori S, Picardi A, Fazi P, Testi AM, Petti MC, Montefusco E, Mandelli F.
    Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
    [Abstract] [Full Text] [Related]

  • 4. Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine.
    Bauduer F, Delmer A, Blanc MC, Delmas-Marsalet B, Cadiou M, Rio B, Marie JP, Zittoun R.
    Leuk Lymphoma; 1993 Jun; 10(3):195-200. PubMed ID: 8220118
    [Abstract] [Full Text] [Related]

  • 5. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
    Barone S, Baer MR, Sait SN, Lawrence D, Block AW, Wetzler M.
    Am J Hematol; 2001 Jun; 67(2):119-24. PubMed ID: 11343384
    [Abstract] [Full Text] [Related]

  • 6. Idarubicin in blastic crisis of chronic myelogenous leukemia.
    Lambertenghi-Deliliers G, Annaloro C, Cortellaro M, Pozzoli E, Oriani A, Polli EE.
    Haematologica; 1991 Jun; 76(5):406-8. PubMed ID: 1806446
    [Abstract] [Full Text] [Related]

  • 7. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P.
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [Abstract] [Full Text] [Related]

  • 8. High-dose cytosine arabinoside and etoposide in the treatment of relapsed or refractory adult leukemia.
    Gryn J, Conroy J, Topolsky D, Crilley P, Kahn SB, Bulova S, Weiss J, Brodsky I.
    Am J Clin Oncol; 1991 Feb; 14(1):52-4. PubMed ID: 1987740
    [Abstract] [Full Text] [Related]

  • 9. Cytosine arabinoside in the management of recurrent leukaemia.
    Ganesan TS, Barnett MJ, Amos RJ, Piall EM, Aherne GW, Man A, Lister TA.
    Hematol Oncol; 1987 Feb; 5(1):65-9. PubMed ID: 3471699
    [Abstract] [Full Text] [Related]

  • 10. A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.
    Lee EJ, Reck K, Carter C, Hodges S, Schiffer CA.
    Leukemia; 1993 Oct; 7(10):1500-3. PubMed ID: 8412310
    [Abstract] [Full Text] [Related]

  • 11. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
    Kantarjian HM, Talpaz M, Kontoyiannis D, Gutterman J, Keating MJ, Estey EH, O'Brien S, Rios MB, Beran M, Deisseroth A.
    J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
    [Abstract] [Full Text] [Related]

  • 12. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
    Katagiri T, Miyazawa K, Uchida Y, Hayashi S, Iwama H, Shyohji N, Kawakubo K, Shimamoto T, Inatomi Y, Kuriyama Y, Yaguchi M, Nehashi Y, Ohyashiki K, Toyama K.
    Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846
    [Abstract] [Full Text] [Related]

  • 13. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.
    Grant S, Baker M, Bhalla K.
    Leukemia; 1993 Dec; 7(12):1933-8. PubMed ID: 8255091
    [Abstract] [Full Text] [Related]

  • 14. High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia.
    Whitlock JA, Wells RJ, Hord JD, Janco RL, Greer JP, Gay JC, Edwards JR, McCurley TL, Lukens JN.
    Leukemia; 1997 Feb; 11(2):185-9. PubMed ID: 9009078
    [Abstract] [Full Text] [Related]

  • 15. FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
    Martinelli G, Testoni N, Zuffa E, Visani G, Zinzani PL, Zaccaria A, Farabegoli P, Arpinati M, Amabile M, Tura S.
    Leuk Lymphoma; 1996 Jun; 22(1-2):173-6. PubMed ID: 8724545
    [Abstract] [Full Text] [Related]

  • 16. A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis.
    Kouides PA, Rowe JM.
    Leuk Res; 1995 Oct; 19(10):763-70. PubMed ID: 7500655
    [Abstract] [Full Text] [Related]

  • 17. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA, DiCarlo J, Groshek P, Kanakura Y, Berg D, Mayer RJ, Griffin JD.
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [Abstract] [Full Text] [Related]

  • 18. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
    Kornblau SM, Cortes-Franco J, Estey E.
    Leukemia; 1993 Mar; 7(3):378-83. PubMed ID: 8445943
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
    Kantarjian HM, Beran M, O'Brien S, Robertson L, Siddik Z, Yoshida M, Yang LY, Rios MB, Keating MJ, Meyer M.
    Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
    [Abstract] [Full Text] [Related]

  • 20. A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.
    Dutcher JP, Morris EL, Gaynor B, Paietta E, Wiernik PH.
    Med Oncol; 2010 Sep; 27(3):728-35. PubMed ID: 19697165
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.